Will Exelixis’ Cabozantinib Miss The Boat In Prostate Cancer?
Exelixis says one pain study may do it for approval, despite losing an SPA with FDA and the agency’s preference for an overall survival endpoint.
Exelixis says one pain study may do it for approval, despite losing an SPA with FDA and the agency’s preference for an overall survival endpoint.